Bifogade filer
The directed share issue to PRS1 ApS is completed
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Magle Chemoswed Holding AB ("Magle Group" or the "Company") announced on 28 June 2024 that it had entered into a merger agreement with PRS1 ApS (the "Seller") regarding the acquisition of all shares in pK Biotech ApS ("pK Biotech") and its subsidiary pK Chemicals A/S. The extraordinary general meeting in Magle Group earlier today, on 4 October 2024, resolved to approve the board of directors' resolution on a directed issue of shares with payment through set-off to the Seller (the "Directed Share Issue"). Magle Group announces through this press release that the Directed Share Issue has now been carried out by the Seller having subscribed and been alloted all shares in the Directed Share Issue.
The purchase price for all shares in pK Biotech was paid in the form of a seller promissory note of approximately SEK 240 million, that today has been offset against 7,200,000 newly issued shares in Magle Group (the "Consideration Shares"). The Consideration Shares have been subscribed for and been allotted to the Seller. The share capital after the Directed Share Issue, and the new issue of merger consideration shares to the shareholders in Amniotics AB (publ) (the "Merger Consideration Issue") announced by the Company earlier today, amounts to SEK 920,095.85 distributed over 18,401,917 shares. The Directed Share Issue of the Consideration Shares corresponds to a dilution of approximately 39.1 percent based on the number of shares and votes in the Company after the Directed Share Issue and the Merger Consideration Issue.
The Consideration Shares are subject to a lock-up undertaking for the Seller and certain of the Seller's ultimate owners for one year from the completion of the acquisition, subject to customary exceptions.
Advisors
Vator Securities AB is financial advisor and Advokatfirman Schjødt is legal advisor to Magle Group in connection with the transaction.
For other enquiries, please contact:
Magle Group
Justin Pierce, CEO
Email: justin.pierce@maglechemoswed.com
Telephone: +46 (0)70 593 58 21
About Magle Group
The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes two operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Learn more on www.maglechemoswed.com and https://maglegroup.com/ and www.maglepharmacept.com.
Vator Securities is Magle Group's certified adviser on Nasdaq First North Growth Market and can be reached at ca@vatorsec.se or +46 (0)8-580 065 99.